Literature DB >> 19995395

NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells.

Rainer Hubmann1, Markus Düchler, Susanne Schnabl, Martin Hilgarth, Dita Demirtas, Dieter Mitteregger, Andrea Hölbl, Katrina Vanura, Trang Le, Thomas Look, Josef D Schwarzmeier, Peter Valent, Ulrich Jäger, Medhat Shehata.   

Abstract

One characteristic of chronic lymphocytic leukaemia (CLL) lymphocytes is high expression of CD23, which has previously been identified as a downstream target for NOTCH2 signalling. The mechanisms regulating NOTCH2-dependent CD23 expression, however, are largely unknown. This study showed that peripheral CLL cells overexpressed transcriptionally active NOTCH2 (N2(IC)), irrespective of their prognostic marker profile. When placed in culture, NOTCH2 activity was spontaneously decreased in 25 out of 31 CLL cases (81%) within 24 h. DNA-bound N2(IC) complexes could be maintained by the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) or by gamma-interferon (IFN-gamma), two CLL characteristic inducers of CD23 expression. Inhibition of PKC-delta by RNA interference or by rottlerin antagonised PMA-induced NOTCH2 activation and also suppressed NOTCH2 activity in CLL cases with constitutively activated NOTCH2 signalling. In 23 out of 29 CLL cases tested (79%), DNA-bound N2(IC) complexes were found to be resistant to the gamma-secretase inhibitor (GSI) DAPT, suggesting that GSIs will be only effective in a subset of CLL cases. These data suggest that deregulation of NOTCH2 signalling is critically involved in maintaining the malignant phenotype of CLL lymphocytes and point to a link between PKC-delta and NOTCH2 signalling in the leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995395     DOI: 10.1111/j.1365-2141.2009.08024.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Signal Transduction in Immune Cells and Protein Kinases.

Authors:  Monica Neagu; Carolina Constantin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  A brief overview of clinical significance of novel Notch2 regulators.

Authors:  Joanna Pancewicz
Journal:  Mol Cell Oncol       Date:  2020-06-30

3.  In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

Authors:  Greta Maria Paola Giordano Attianese; Virna Marin; Valentina Hoyos; Barbara Savoldo; Irene Pizzitola; Sarah Tettamanti; Valentina Agostoni; Matteo Parma; Maurilio Ponzoni; Maria T S Bertilaccio; Paolo Ghia; Andrea Biondi; Gianpietro Dotti; Ettore Biagi
Journal:  Blood       Date:  2011-03-15       Impact factor: 22.113

Review 4.  Current views on the role of Notch signaling and the pathogenesis of human leukemia.

Authors:  Joanna Pancewicz; Christophe Nicot
Journal:  BMC Cancer       Date:  2011-11-30       Impact factor: 4.430

5.  The emerging roles of Notch signaling in leukemia and stem cells.

Authors:  Na Liu; Jingru Zhang; Chunyan Ji
Journal:  Biomark Res       Date:  2013-07-18

6.  Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.

Authors:  S Giunco; A Celeghin; K Gianesin; R Dolcetti; S Indraccolo; A De Rossi
Journal:  Cell Death Dis       Date:  2015-05-28       Impact factor: 8.469

7.  Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.

Authors:  Rainer Hubmann; Wolfgang Sieghart; Susanne Schnabl; Mohammad Araghi; Martin Hilgarth; Marlies Reiter; Dita Demirtas; Peter Valent; Christoph Zielinski; Ulrich Jäger; Medhat Shehata
Journal:  Front Pharmacol       Date:  2017-07-07       Impact factor: 5.810

8.  Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL.

Authors:  Rainer Hubmann; Susanne Schnabl; Mohammad Araghi; Christian Schmidl; André F Rendeiro; Martin Hilgarth; Dita Demirtas; Farghaly Ali; Philipp B Staber; Peter Valent; Christoph Zielinski; Ulrich Jäger; Medhat Shehata
Journal:  Cells       Date:  2020-06-18       Impact factor: 6.600

9.  Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases.

Authors:  Masahiro Ono; Reiko J Tanaka; Manabu Kano; Toshio Sugiman
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

Review 10.  Protein kinase C in cellular transformation: a valid target for therapy?

Authors:  Anuradha Tarafdar; Alison M Michie
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.